Corcept Therapeutics Incorporated
CORT
Classement en actions
#1694
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Prix de l'action
$116.87
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$12.63B
Changement (1 jour)
4.25%
Changement (1 an)
55.01%
Pays
US
Échange Corcept Therapeutics Incorporated (CORT)
Catégorie
Healthcare
Revenus pour Corcept Therapeutics Incorporated (CORT)
Revenus en Jun 2026 TTM : $830.81M
Selon les derniers rapports financiers de Corcept Therapeutics Incorporated, le chiffre d'affaires actuel de l'entreprise (TTM) est de $830.81M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $482.38M une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de $401.86M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Corcept Therapeutics Incorporated de 2001 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $830.81M | 23.08% |
| 2024 | $675.04M | 39.94% |
| 2023 | $482.38M | 20.04% |
| 2022 | $401.86M | 9.80% |
| 2021 | $365.98M | 3.42% |
| 2020 | $353.87M | 15.46% |
| 2019 | $306.49M | 21.99% |
| 2018 | $251.25M | 57.82% |
| 2017 | $159.20M | 95.77% |
| 2016 | $81.32M | 61.72% |
| 2015 | $50.29M | 89.39% |
| 2014 | $26.55M | 156.36% |
| 2013 | $10.36M | 213.18% |
| 2012 | $3.31M | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | -100.00% |
| 2009 | $29.00K | -86.12% |
| 2008 | $209.00K | -56.64% |
| 2007 | $482.00K | 63.95% |
| 2006 | $294.00K | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $2.54B | 205.24% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $4.88B | 487.88% |
HK
|
